• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Three Rivers Medical wins CE Mark for Rio aneurysm embolization device

Three Rivers Medical wins CE Mark for Rio aneurysm embolization device

February 21, 2018 By Brad Perriello

Three Rivers MedicalThree Rivers Medical said yesterday that it won CE Mark approval in the European Union back in October for its Rio embolization coil for treating brain aneurysms.

Mountain View, Calif.-based Three Rivers said it also treated the first 10 patients with the Rio device, which is also CE Marked for peripheral embolizations. The company said it plans to go to market via distributor in territories that recognize the mark.

“The use of embolization coils to treat intracranial aneurysms continues to be the global gold standard for therapeutic neurovascular interventions and is proven to be safe and effective for both ruptured and unruptured aneurysms,”CEO Gibb Clarke said in prepared remarks. “I personally attended and trained our customers for the first 10 cases. Our coils were used in challenging and complex cases and in all circumstances performed exceptionally well. Our coil performance was complimented by our novel mechanical detachment system with a first-of-its-kind visual detachment confirmation, providing our customers with both immediate and visual fluoroscopic confirmation of successful coil detachment. For a small emerging company intent on making an impact on this market, a competitive coil line is a great place to start. As a company we have our eye on developing an expanded product portfolio that is complementary to our Rio embolization coil system.”

In addition to the Rio coil, Three Rivers said it’s developing a pipeline of complementary products.

“Three Rivers Medical’s major strategic value to the growing interventional neuro market is in our ability to develop innovative interventional products rapidly and in a cost efficient manner without compromising quality. The process is complimented by our broad network of international distributors and physicians who provide critical design input to our product development process,” R&D VP Dean Carson added.

“I evaluated the Rio coil in two complex multi-lobe aneurysms and the Rio coil allowed me to effectively pack these difficult aneurysms. The ultrasoft coils were very compliant giving me exceptional microcatheter stability and the visual detachment system gave me instant confirmation of successful coil detachment, highly valuable information in my opinion,” Dr. Wojciech Poncyljusz of Hospital Szczecin Poland said in a press release.

Filed Under: Endoscopic, Neurological, Regulatory/Compliance Tagged With: Three Rivers Medical

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy